A compound of Formula I,

##STR00001##

is disclosed. In Formula I, M is Pd or Pt; each of X.sup.1 to X.sup.12 is C or N; each of X.sup.13 and X.sup.14 is CH, CD or N; each of Z.sup.1, Z.sup.2, and Z.sup.3 is C or N; L.sup.1 is selected from a variety of bivalent linkers; X is selected from O, S, Se, NR′, and CR″R′″; each R, R′, R.sup.1, R.sup.2, R.sup.3, R.sup.A, R.sup.B, R.sup.C, R.sup.D, and R.sup.E is hydrogen or a General Substituent; at least one of Z.sup.1, Z.sup.2, and Z.sup.3 is a carbon atom substituted with a substituent with a molecular weight of at least 16. Formulations, OLEDs, and consumer products that include Formula I are also disclosed.

A compound is represented by a formula (1). n is 2 to 4, m is 1 to 4, q is 0 to 3, and m+n+q=6; CN is a cyano group; D.sub.1 is a group represented by a formula (2), (3) or (3X), the plurality of D.sub.1 are the same; and Rx is a hydrogen atom or substituent. R.sub.1 to R.sub.8 are each independently a hydrogen atom or substituent. R.sub.31 to R.sub.38 and R.sub.41 to R.sub.48 are each independently a hydrogen atom or substituent; p, px and py are each independently 1 to 4; A to C are each independently a cyclic structure represented by a formula (131) or (132). R.sub.19 and R.sub.20 are each independently a hydrogen atom or substituent. X.sub.1 is a sulfur atom or the like, and * represents a bonding position with a carbon atom of a benzene ring in the formula (1).

##STR00001##

A compound is represented by a formula (1). n is 2 to 4, m is 1 to 4, q is 0 to 3, and m+n+q=6; CN is a cyano group; D.sub.1 is a group represented by a formula (2), (3) or (3X), the plurality of D.sub.1 are the same; and Rx is a hydrogen atom or substituent. R.sub.1 to R.sub.8 are each independently a hydrogen atom or substituent. R.sub.31 to R.sub.38 and R.sub.41 to R.sub.48 are each independently a hydrogen atom or substituent; p, px and py are each independently 1 to 4; A to C are each independently a cyclic structure represented by a formula (131) or (132). R.sub.19 and R.sub.20 are each independently a hydrogen atom or substituent. X.sub.1 is a sulfur atom or the like, and * represents a bonding position with a carbon atom of a benzene ring in the formula (1).

##STR00001##

Described herein are PARP1 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of cancer.

Described herein are PARP1 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of cancer.

The invention provides tricyclic compounds and their use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making various tricyclic compounds are provided. The compounds are contemplated to have activity against methionyl aminopeptidase 2.

The invention provides tricyclic compounds and their use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making various tricyclic compounds are provided. The compounds are contemplated to have activity against methionyl aminopeptidase 2.

The present application relates to a compound which contains an indenocarbazole group, a particular arylamino group and an electron-deficient group bonded to the indenocarbazole group. The compound is suitable for use in electronic devices, in particular in organic electroluminescent devices.

The present application relates to a compound which contains an indenocarbazole group, a particular arylamino group and an electron-deficient group bonded to the indenocarbazole group. The compound is suitable for use in electronic devices, in particular in organic electroluminescent devices.

Disclosed are compounds of formula (I) wherein A is CH or N, B is CR or N; and D is CR; R represents hydrogen, OH or NH.sub.2; R1 and R2, independently of each other, represent hydrogen, N(R3).sub.2, halogen, cyano, nitro, R4-C1-C4alkyl, R4-C1-C4halogenoalkyl, OH, R4-C1-C4alkoxy, R4-C1-C4halogenoalkoxy, SH, R4-C1-C4alkythio, R4-C1-C4halogenoalkylthio; R3 represents, independently at each occurrence, hydrogen, R4-C1-C4alkyl or R4-C1-C4halogenoalkyl; R3a represents, independently at each occurrence, hydrogen or C1-C4 alkyl; R4 represents, independently at each occurrence, hydrogen, halogen, cyano, OH, SH, NH.sub.2, NH(CH.sub.3) or N(CH.sub.3).sub.2; X represents a group of formula -E- or -E-F—, wherein E and F are different from each other and represent a group selected from —C(R3a)2-, —(C═O)—, —NR3a- and —O— and F is linked to Y, with the proviso that if X represents -E-F— one of E or F represents —C(R3a).sub.2- or —(C═O)—; Y represents a group selected from C1-C6alkyl, mono- or bicyclic C3-C11cycloalkyl, which may be partially unsaturated, mono- or bicyclic 3 to 11-membered heterocycloalkyl, which may be partially unsaturated, a mono- or bicyclic group comprising at least one aryl or heteroaryl cycle, wherein said heterocycloalkyl group and said group comprising at least one heteroaryl cycle comprise one or more heteroatoms selected from nitrogen, oxygen and sulfur and said group Y is either unsubstituted or substituted by one or more substituents and comprises including its substituents one or more than one nitrogen atom having a lone electron pair; and Z represents a mono- or bicyclic group comprising at least one aryl or heteroaryl cycle, said heteroaryl cycle comprising one or more heteroatoms selected from nitrogen, oxygen and sulfur, which aryl or heteroaryl group is unsubstituted or substituted by one or more substituents; including tautomers of said compounds, mixtures of two tautomeric forms of said compounds, and pharmaceutically acceptable salts of said compounds, tautomers thereof or mixtures of two tautomeric forms thereof, preferably with the proviso that Y comprises one or more primary amino group —NH.sub.2, when X represents —(C═O)— or —(C═O)—NR3a-, wherein R3a represents hydrogen or C1-C4alkyl; which are useful for the treatment of proliferation disorders or diseases, such as cancer.

##STR00001##